Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

22 Apr 2016

Abstract excerpt

Rheumatology key message Catastrophic antiphospholipid syndrome is associated with excessive complement activation explaining the clinical efficacy of complement inhibitory treatment. S ir , Research suggests that the complement system plays a role in the pathophysiology of APS, and experimental studies have revealed a requirement for C5 in APS-induced thrombus formation [ 1 ]. However, limited data are available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes and associated disorders
Share to Peripheral Neuropathies and Disorders
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27105662
DOI: 10.1093/rheumatology/kew040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndromePMID 27105662Read ↗

Complement in antiphospholipid syndrome, time to target?Semantic proximity Read ↗

Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic ImplicationsSemantic proximity Read ↗

Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.Semantic proximity Read ↗

Catastrophic antiphospholipid syndrome accompanied by complement regulatory gene mutation.Semantic proximity Read ↗

A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitorSemantic proximity Read ↗

Diagnosis and management of catastrophic antiphospholipid syndrome.Semantic proximity Read ↗

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?Semantic proximity Read ↗

Clinical and laboratory features of the catastrophic antiphospholipid syndrome.Semantic proximity Read ↗

Complement analysis 2016: Clinical indications, laboratory diagnostics and quality controlSemantic proximity Read ↗

Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical PathwaySemantic proximity Read ↗

The complement alternative pathway and hemostasisSemantic proximity Read ↗

Complement, inflammation and thrombosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.